Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Inhibition of CDK Activity

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

cAMP-dependent Protein Kinase Pathways

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Species differences in opsonization and phagocyte recognition of preclinical poly-2-alkyl-2-oxazoline-coated nanoparticles.

Nature communications·2025

Same author

The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports.

European review for medical and pharmacological sciences·2021

Same author

Sensitivity and specificity values of high-risk HPV DNA, p16/ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL).

European review for medical and pharmacological sciences·2019

Same author

Hydrophobic Derivatives of Glycopeptide Antibiotics as Inhibitors of Protein Kinases.

Biochemistry. Biokhimiia·2018

Same author

Cervical carcinogenesis, bacterial vaginosis, HPV-mRNA test and relapse of CIN2+ after loop electrosurgical excision procedure (LEEP).

European review for medical and pharmacological sciences·2017

Same author

Comparative effectiveness and impact on health-related quality of life of hysterectomy vs. levonorgestrel intra-uterine system for abnormal uterine bleeding.

European review for medical and pharmacological sciences·2017

Same journal

Screening of Medicinal and Edible Homology Substances for Diabetic Kidney Disease Based on GraphBAN.

Current medicinal chemistry·2026

Same journal

Berberine as an Antimicrobial Agent and Gut Microbiota Modulator: Mechanisms and Therapeutic Potential.

Current medicinal chemistry·2026

Same journal

Research Progress of Grapefruit-derived Extracellular Vesicles in Anti-tumor Treatment.

Current medicinal chemistry·2026

Same journal

Corrigendum to: Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke.

Current medicinal chemistry·2026

Same journal

Ferroptosis and Its Crosstalk with Other Cell Death Modes in Ischemic Stroke.

Current medicinal chemistry·2026

Same journal

Integrative Analysis Reveals BPTF, COL1A1, and COL4A2 as Fibroblast-Related Biomarkers Associated with Immune Infiltration in Ovarian Cancer.

Current medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 16, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Kinase CK2 inhibition: an update.

G Cozza¹, L A Pinna, S Moro

¹Department of Biomedical Sciences, University of Padova, Padova, Italy.

Current Medicinal Chemistry

|December 6, 2012

Summary

This summary is machine-generated.

Protein kinase CK2 (Casein Kinase 2) is crucial in human diseases. This review details ATP-competitive and novel non-ATP-competitive inhibitors, highlighting their potential for new drug discovery.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Assaying the Kinase Activity of LRRK2 in vitro

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Related Experiment Videos

Last Updated: May 16, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Assaying the Kinase Activity of LRRK2 in vitro

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Area of Science:

Biochemistry and Molecular Biology
Medicinal Chemistry
Pharmacology

Background:

Protein kinase CK2 (Casein Kinase 2) is a vital enzyme involved in numerous cellular processes.
Dysregulation of CK2 activity is linked to various human diseases, including cancer.
Existing CK2 inhibitors are primarily ATP-competitive, with limited clinical progression.

Purpose of the Study:

To comprehensively review existing chemical classes of CK2 inhibitors.
To explore both conventional ATP-competitive and emerging non-ATP-competitive inhibitors.
To identify promising avenues for novel drug candidate development targeting CK2.

Main Methods:

Literature review of scientific publications and patent databases.
Analysis of chemical structures and inhibition mechanisms of CK2 inhibitors.
Evaluation of the therapeutic potential and drug development status of identified inhibitors.

Main Results:

Several classes of ATP-competitive CK2 inhibitors have been identified, with CX-4945 progressing to Phase I clinical trials.
Non-ATP-competitive inhibitors represent a novel and underexplored area for CK2 targeting.
Diverse chemical scaffolds demonstrate potential for selective CK2 inhibition.

Conclusions:

CK2 inhibitors hold significant therapeutic promise for various diseases.
Non-ATP-competitive inhibitors offer a new frontier for drug discovery and overcoming resistance.
Further research into novel CK2 inhibitors is warranted for developing effective drug candidates.